AnneMFavretMD

Oncology • Fairfax, VA

Hematologic Oncology

Physician

Join to view full profile

Dr. Favret is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Favret's full profile

Already have an account?

Office
8503 Arlington Blvd
Suite 400
Fairfax, VA 22031
Phone(703) 280-5390
Fax(703) 280-9596
Is this information wrong?

Education & Training

Stanford UniversityFellowship, Medical Oncology, 1996 - 1999
Georgetown University HospitalResidency, Internal Medicine, 1993 - 1996
Temple University School of MedicineClass of 1993

Certifications & Licensure

CA State Medical License 1996 - Present
VA State Medical License 1994 - 2022
American Board of Internal Medicine Medical Oncology

Clinical Trials

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Jan 01Clinical Contact
A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease Start of enrollment: 2013 Dec 01Novartis Pharmaceuticals

Publications & Presentations

PubMed

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer.
Joanne L. Blum, Nicholas J. Robert, Jay Andersen, Anne Favret, Patrick J. Ward, Cynthia Osborne, John Pippen> ;Journal of Clinical Oncology. 2017 Dec 11
Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices
Neelima Denduluri, Debra A. Patt, Yunfei Wang, Menaka Bhor, Xiaoyan Li, Anne Favret, Phuong Khanh Morrow, Richard Barron, Lina Asmar, Shanmugapriya Saravanan, Yanli Li...> ;Journal of The National Comprehensive Cancer Network. 2015 Nov 1
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study
Stephen E. Jones, Rufus P. Collea, Devchand Paul, Scot Sedlacek, Anne Favret, Ira Gore, Deborah Lindquist, Frankie Ann Holmes, Mary Ann K Allison, Barry Don Brooks, Ra...> ;Lancet Oncology. 2013 Oct 1
Concordance between the 21-gene recurrence score (RS) and the 70-gene profile (MP) in breast cancer (BC) patients (pts).
Denduluri N, Rugo HS, Davis SE, Favret A, Hong R, Au A, Moore DH, Esserman L> ;J. Clin. Oncol.. 2011-09-20
Dose Intensity in Early-Stage Breast Cancer: A Community Practice Experience
Robert L. Bretzel, Ralph Cameron, Marc Gustas, Maria A. Garcia, Heather K. Hoffman, Rosalind Malhotra, Karen Miller, Janine Prime, Anne Favret> ;Journal of Oncology Practice. 2009 Nov 1
HER2-Positive Advanced Breast Cancer
Nicholas J. Robert, Anne M. Favret> ;Hematology-oncology Clinics of North America. 2007 Apr 1
Locally advanced breast cancer: is surgery necessary?
Anne M. Favret, Robert W. Carlson, Donald R. Goffinet, Stefanie S. Jeffrey, Frederick M. Dirbas, Frank E. Stockdale> ;Breast Journal. 2001 Mar 1
Multidisciplinary Management of Locally Advanced Breast Cancer.
Robert W. Carlson, Anne M. Favret> ;Breast Journal. 1999 Sep 1
Join now to see all